Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.